A recent study has uncovered startling statistics about the risk of genetic Alzheimer's disease among a significant segment of the American population.
The study, led by Dr. Juan Fortea from the Sant Pau Research Institute in Barcelona, Spain, suggests that over 6 million Americans face the possibility of developing genetic Alzheimer's, driven by the APOE4 gene, with a striking 95% strike rate by the age of 65.
The APOE4 Gene
Dr. Fortea, the director of the Memory Unit at the Neurology Service of Sant Pau Hospital, highlighted the significance of this research, indicating that individuals carrying two copies of the APOE4 gene, known as APOE4 homozygotes, demonstrate distinct biological markers associated with Alzheimer's disease.
These findings challenge conventional understanding, suggesting that the APOE4 gene may not just be a risk factor but a primary driver of genetic Alzheimer's.
The study underscores the prevalence of this genetic predisposition within the population. Dr. Fortea noted that 2-3% of individuals with duplicated APOE4 genes could represent a staggering 6.62 to 9.93 million Americans.
This genetic susceptibility is inherited through a genetic lottery, where individuals inherit the same APOE gene from both parents.
The researchers drew their conclusions after evaluating a substantial cohort of individuals, analyzing data from brain donors and clinical cohorts across Europe and the United States.
Their analysis revealed that APOE4 homozygotes exhibited Alzheimer's-related biomarkers at an earlier age than individuals with other APOE gene variants.
The Need for Early Preventive Strategies
The study's findings may have profound implications for understanding Alzheimer's disease and devising preventive strategies.
Dr. Fortea emphasized the need for individualized prevention approaches and clinical interventions tailored to this genetic population.
The study suggests that monitoring individuals with two copies of the APOE4 gene from an early age could be critical for implementing effective preventive measures.
Dr. Alberto Lleó, a researcher at the Dementia Neurobiology Group at IR Sant Pau, highlighted the importance of these findings in advancing personalized treatment approaches. He emphasized that having two copies of the APOE4 gene not only increases the risk of Alzheimer's but also accelerates its onset.
Moreover, Dr. Víctor Montal, who contributed to the study during his tenure at Sant Pau and now researches the molecular structure of the APOE gene at the Barcelona Supercomputing Center, emphasized the necessity of early monitoring for preventive interventions.
"These data represent a reconceptualization of the disease or of what it means to be homozygous for the APOE4 gene. This gene has been known for over 30 years and was known to be associated with an increased risk of developing Alzheimer's disease," Dr. Juan Fortea said in a press release statement.
"But now we know that virtually all people who have this duplicated gene develop the biology of Alzheimer's. This is important because they are between 2 and 3% of the population."
The study findings were published in the journal Nature.
Related Article : Erectile Dysfunction Drugs Can Reduce Risk of Alzheimer's Disease, New Research Claims
